Mount Sinai Designated as National Cancer Institute Proteogenomics Data Analysis

National Cancer Institute Proteogenomics

National Cancer Institute Proteogenomics

Will produce prospective biomarkers and drug targets, and new insights into cancer biology


The Office of Cancer Scientific Proteomics Research at the National Cancer Institute (NCI) has actually granted $4.2 million over five years to Mount Sinai scientists developing a Proteogenomic Data Analysis Center (PGDAC) to advance cancer research study and treatments. Proteogenomics, which studies the functions of proteins and genes within a cell or organism, is an essential area of expedition to even more our understanding of cancer.

The award supports the Center’s work to identify potential biomarkers and drug targets for cancer, brand-new insights into cancer biology, and bioinformatics tools to allow advanced expedition and discovery from cancer-related datasets.

The Center’s lead private investigators, Pei Wang, PhD, Professor, Genetic and Genomic Sciences, and Avi Ma’ayan, PhD, Professor, Pharmacological Sciences, and Director of the Mount Sinai Center for Bioinformatics, will leverage their proficiency in statistics/biostatistics, maker knowing, data integration, systems pharmacology, and proteomics data modeling to further understand the proteogenomic complexity of growths.

The centers of quality belong to NCI’s Scientific Proteomic Growth Analysis Consortium (CPTAC) program, a nationwide effort to advance and speed up cancer research through the application of proteogenomics. Mount Sinai is one of 14 CPTAC centers nationwide.

Information produced and tools developed by the CPTAC centers will be made available to the general public to help further advance and accelerate cancer research.

READ  Proteomics International Laboratories' (ASX: PIQ) diabetic kidney illness tests ranked above current requirement of care